Role of carnitine supplementation in reducing anthracycline-induced cardiotoxicity: Call for further research

Dear Editor, We wrote this paper to draw attention to the expanding body of research suggesting that carnitine supplements may help cancer patients experience less anthracycline-induced cardiotoxicity. Although anthracyclines are very efficient in treating a wide range of malignancies, they also increase the chance of developing long-term heart problems. Understanding and controlling the side effects of chemotherapy is becoming more and more crucial as the number of cancer survivors rises. Carnitine may help lessen the cardiotoxic effects of anthracyclines, according to recent research that has started to look at the connection between these patients’ heart health and serum carnitine levels.[1] However, a number of crucial concerns must be resolved in order to completely comprehend the potential of such medications as a therapeutic approach. Theoretically, it is challenging to draw firm conclusions from a small study because of the tiny cohort size, which also lowers statistical power. The reproducibility of the findings and the evidence supporting the cardioprotective effects of carnitine supplementation would both be enhanced by extending these trials to larger patient populations. Larger studies would also enable more thorough subgroup analysis to identify patient populations—such as particular age groups, cancer kinds, and treatment stages—that are most likely to benefit from this strategy. The quality control of laboratory carnitine concentration testing is another crucial concern. It is challenging to clearly show a link between carnitine levels and cardiac outcomes due to variations in assay sensitivity, precision, and accuracy. To guarantee accurate and repeatable results, laboratory techniques must incorporate strict quality control measures. Additionally, transparent reporting of these methods enhances cross-study comparability and increases scientific community transparency. Confounding variables that could influence carnitine levels and heart function should be taken into account in addition to technical issues. For instance, carnitine metabolism is significantly influenced by nutritional status, and cancer patients frequently undergo dietary modifications as part of their therapy. Carnitine levels and heart health may also be impacted by other drugs taken concurrently with chemotherapy. By controlling for these variables, research could better understand how carnitine works on its own to prevent cardiotoxicity and make sure that the results are not the result of outside influences. Despite the encouraging initial findings, it is unclear if carnitine supplementation should be used in clinical practice since it may lower the incidence of cardiac events linked to anthracycline treatment. To find out if carnitine supplementation will lessen the frequency or intensity of cardiotoxicity in patients undergoing high-dose chemotherapy, larger randomized controlled trials are required. These studies aim to investigate both immediate and long-term impacts, including possible advantages for young cancer survivors who might be at risk for heart disease for the rest of their lives. There are a number of intriguing directions for further study in the future. The long-term effects of carnitine supplementation may be better understood with the help of long-term research in a variety of patient populations. Further information on carnitine’s potential as a treatment may be obtained by examining the processes via which it influences heart healing and mitochondrial function. The viability of adding carnitine supplements to standard cancer treatment will also need to be evaluated through cost-effectiveness studies, especially in groups with a high risk of cardiotoxicity. In conclusion, although studies on carnitine supplementation as a means of lowering anthracycline-induced cardiotoxicity are still in their early stages, the data thus far suggest that carnitine may be a useful oncology treatment. In conclusion, it is necessary to conduct larger, more meticulous research that tackles methodological issues, takes confounding factors into account, and looks at long-term results. The health of cancer survivors continues to be our top priority. A significant step in enhancing the quality of life for patients and survivors is figuring out how to lessen the effects of chemotherapy on the heart and blood arteries. Acknowledgment None. Author contributions HP: 50% ideas, writing, analyzing, approval. VW: 50% ideas, supervision, approval. Data availability statement No new data generated. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.